Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.
Bucciardini R, D'Ettorre G, Baroncelli S, Ceccarelli G, Parruti G, Weimer LE, Fragola V, Galluzzo CM, Pirillo MF, Lucattini S, Bellagamba R, Francisci D, Ladisa N, Degli Antoni A, Guaraldi G, Manconi PE, Vullo V, Preziosi R, Cirioni O, Verucchi G, Floridia M; ISS-NIA study group.
Bucciardini R, et al. Among authors: d ettorre g, francisci d.
Int J STD AIDS. 2012 Jul;23(7):459-63. doi: 10.1258/ijsa.2012.011391.
Int J STD AIDS. 2012.
PMID: 22843997
Clinical Trial.